Palabras clave
Microbiología
Virología parvovirus B-19 humano
Virus Infectious diseases
Microbiology
Virology
Human parvovirus B19
Viruses
Cómo citar
Resumen
Desde su descubrimiento casual e implicación como patógeno humano asociado con crisis aplásica transitoria y el eritema infeccioso, el parvovirus B19 humano se ha relacionado con un amplio espectro de enfermedades, cada una con manifestaciones clínicas especiales, importantes desde el punto de vista científico y epidemiológico. Lo anteriormente citado ha llevado a la medicina moderna cada día a estudiar más a fondo sus características estructurales y formas de transmisión, así como el comportamiento del sistema inmune frente a la infección. Actualmente no existe un tratamiento específico y solo bajo condiciones especiales se recomienda el uso de gammaglobulina. Presentamos una revisión narrativa actualizada a 2011 de los principales aspectos relacionados con parvovirus B19.
Citas
Cossart YE, Field AM, Cant B, Widdows D, Parvoviruslike particles in human sera. Lancet 1975; 1:72. https://doi.org/10.1016/S0140-6736(75)91074-0
Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483. https://doi.org/10.1128/JCM.37.8.2483-2487.1999
Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987; 6:711. https://doi.org/10.1097/00006454-198708000-00003
Kelly HA, Siebert D, Hammond R, Leydon J. The agespecific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 2000; 124:449-457. https://doi.org/10.1017/S0950268899003817
Yamashita K, Matsunaga Y, Taylor-Wiedeman J, Yamazaki S. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn J Med Sci Biol 1992; 45:49. https://doi.org/10.7883/yoken1952.45.49
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151. https://doi.org/10.1099/00222615-25-2-151
Public Health Laboratory Service Working Party on Fifth Disease. 1990. Prospective study of human parvovirus (B19) infection in pregnancy. Br Med J 300:1166-1170. https://doi.org/10.1136/bmj.300.6733.1166
Azzi A, Morfini M, Mannucci PM. The transfusion associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204. https://doi.org/10.1016/S0887-7963(99)80033-9
Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine: summary of a workshop. Transfusion 2001; 41:130-5. https://doi.org/10.1046/j.1537-2995.2001.41010130.x
Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061. https://doi.org/10.1001/jama.1990.03440150069028
Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37. https://doi.org/10.1016/S0002-9378(96)70370-8
Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75:97. https://doi.org/10.1046/j.1423-0410.1998.7520097.x
Parrish CR. Pathogenesis of feline panleukopenia virus and canine parvovirus. Baillieres Clin Haematol 1995; 8:57-71. https://doi.org/10.1016/S0950-3536(05)80232-X
Berns K. Parvoviridae: the viruses and their replication, Fields virology Lippincott-Raven, Philadelphia, Pa. 1996 p. 2173-97.
International Committee on Taxonomy of Viruses. 2000. Virus taxonomy: classification and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses. Springer-Verlag, Vienna, Austria.
Berns KI, Bohenzky RA. Adeno-associated viruses: an update. Adv. Virus Res.1987; 32:243-306. https://doi.org/10.1016/S0065-3527(08)60479-0
Deiss V, Tratschin JD, M Weitz, Siegl G. Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini. Virology 1990; 175:247-254. https://doi.org/10.1016/0042-6822(90)90205-6
Moffatt S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70:8485. https://doi.org/10.1128/JVI.70.12.8485-8491.1996
Kaufmann B, Simpson, AA, Rossmann, MG. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. USA 2004; 101:11628. https://doi.org/10.1073/pnas.0402992101
Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 1993; 262:114. https://doi.org/10.1126/science.8211117
Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192. https://doi.org/10.1056/NEJM199404283301704
Ozawa K, Ayub J, Kajigaya S, Shimada T, Young NS. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62:2884-9. https://doi.org/10.1128/JVI.62.8.2884-2889.1988
Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72:3018-28. https://doi.org/10.1128/JVI.72.4.3018-3028.1998
Kaufmann B, Baxa U, Chipman, PR, et al. Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology 2005; 332:189. https://doi.org/10.1016/j.virol.2004.11.037
Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586. https://doi.org/10.1056/NEJMra030840
Norbeck O, Isa A, Pohlmann C, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117. https://doi.org/10.1128/JVI.79.18.12117-12121.2005
Von Poblotzki A, Gerdes C, Reischl U, et al. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70:7327. https://doi.org/10.1128/JVI.70.10.7327-7330.1996
Serjeant BE, Hambleton RR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358:1779- 80. https://doi.org/10.1016/S0140-6736(01)06807-6
Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411. https://doi.org/10.1182/blood.V67.5.1411.1411
Wagner AD, Goronzy JJ, Matteson EL, Weyand CM. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995; 70:261. https://doi.org/10.4065/70.3.261
Heegaard ED, Brown KE, Human Parvovirus B19. Clin Microbiol Rev 2002;15: 485-505. https://doi.org/10.1128/CMR.15.3.485-505.2002
Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166. https://doi.org/10.1136/bmj.300.6733.1166
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA. Clinical manifestations of human parvovirus B19 in adults. Arch. Intern. Med. 1989; 149:1153-56. https://doi.org/10.1001/archinte.149.5.1153
Zerbini M, Musiani M, Venturoli S, Gallinella G, Gibellini D, Gentilomi G, et al. Different syndromes associated with B19 parvovirus viraemia in paediatric patients: report of four cases. Eur. J. Pediatr. 1992;151:815-817. https://doi.org/10.1007/BF01957931
Heegaard ED, Taaning EB. Parvovirus B19 and parvovirus V9 are not associated with Henoch-Schonlein purpura in children. Pediatr Infect Dis J 2002; 21:31. https://doi.org/10.1097/00006454-200201000-00007
Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257. https://doi.org/10.1093/infdis/152.2.257
Woolf AD, Campion GV, Chishick, A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153. https://doi.org/10.1001/archinte.1989.00390050111022
Schwarz TF, Wiersbitzky S, Pambor M. Case report: Detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43:171. https://doi.org/10.1002/jmv.1890430214
Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 2000; 27:2444.
Oguz F, Akdeniz C, Unuvar E, et al. Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J Paediatr Child Health 2002; 38:358. https://doi.org/10.1046/j.1440-1754.2002.00789.x
Soderlund M, Von Essen R, Haapasarri J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063. https://doi.org/10.1016/S0140-6736(96)09110-6
Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53:459. https://doi.org/10.1099/jmm.0.05485-0
Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:8227. https://doi.org/10.1073/pnas.95.14.8227
Morgan-Capner, P, Crowcroft, NS. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health 2002; 5:59.
Haan TR, Akker ES, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76. https://doi.org/10.1111/j.1471-0528.2007.01555.x
Kuhl U. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965. https://doi.org/10.1161/CIRCULATIONAHA.105.548156
Tschope C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879. https://doi.org/10.1161/01.CIR.0000155615.68924.B3
Donoso Mantke O, Nitsche A, Meyer R, et al. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 2004; 31:32. https://doi.org/10.1016/j.jcv.2003.12.013
Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotizing vasculitis: Opportunistic infection or aetiological agent? Lancet 1994; 1:1255. https://doi.org/10.1016/S0140-6736(94)92152-0
Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci 2006; 51:1712. https://doi.org/10.1007/s10620-005-9061-5
Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia colibased VP1 EIA for detection of human parvovirus B19 immunoglobulin IgM and immunoglobulin IgG in sera of pregnant women. J Clin Microbiol 2000; 38:1472. https://doi.org/10.1128/JCM.38.4.1472-1475.2000
Kerr S, O'Keeffe G, Kilty, C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179. https://doi.org/10.1002/(SICI)1096-9071(199902)57:2<179::AID-JMV16>3.0.CO;2-T
Erdman DD. Human parvovirus B19: Laboratory diagnosis. In: Monographs in Virology: Human Parvovirus B19, Anderson, LJ, Young, NS (Eds), Karger, New York 1997. p. 93. https://doi.org/10.1159/000061678
Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia colibased VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J Clin Microbiol 2000; 38:1472. https://doi.org/10.1128/JCM.38.4.1472-1475.2000
Butchko AR, Jordan JA. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. J Clin Microbiol 2004; 42:3191. https://doi.org/10.1128/JCM.42.7.3191-3195.2004
Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061. https://doi.org/10.1001/jama.1990.03440150069028
Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675. https://doi.org/10.1086/368382
ClinicalTrials.gov. B-19 parvovirus vaccine study by clinical trials. Disponible en http://clinicaltrials.gov/ct2/show/NCT00379938 (Evaluado el 20 de Octubre de 2010) Fecha de consulta: Septiembre 2010.
Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP, Impaired Gamma Interferon Responses against Parvovirus B19 by Recently Infected Children, J. Virol, 2000; 74 (21), 9903-9910. https://doi.org/10.1128/JVI.74.21.9903-9910.2000